Compare
AbbVie vs Roivant Sciences (ABBV vs ROIV)
The two stocks side by side, as of the latest close. Performance is rebased to 100 at the start of the window.
Over the past year AbbVie (ABBV) returned +34.4% and Roivant Sciences (ROIV) +92.2%; so far this year the figures are +27.5% and +79.2%.
AbbVie is the larger company by market value, about 18.3 times the size of Roivant Sciences.
Revenue grew +10.7% at ABBV and -67.6% at ROIV over the last year.
ABBV yields 2.38%. ROIV pays no dividend.
Data as of the latest close. Not investment advice.
Relative performance
| ABBV | ROIV | |
|---|---|---|
| Price | $291.31 | $38.88 |
| 1-day | +1.07% | +6.17% |
| YTD | +27.49% | +79.17% |
| 1 year | +34.39% | +92.19% |
| 3 years | +104.47% | +329.14% |
| Market cap | $514.9B | $28.1B |
| P/E | 50.1 | — |
| P/S | 7.80 | 3,728.61 |
| P/B | — | 6.64 |
| Revenue growth | +10.70% | -67.60% |
| EPS growth | +340.20% | — |
| Gross margin % | 73.7 | — |
| Net margin % | 15.7 | -3,535.0 |
| ROE % | — | -6.3 |
| Debt / equity | — | 0.08 |
| FCF yield % | 3.7 | -3.0 |
| Dividend yield % | 2.38 | — |
| Beta | -0.03 | 1.09 |
| RSI (14) | 59.7 | 59.8 |
| Technical rating |